Small Cell Lung Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Non-Small Cell Lung Cancer Driven by Several Mutations - Specialty Pharmacy Times



Non-Small Cell Lung Cancer Driven by Several Mutations 
Specialty Pharmacy Times
Despite improved treatments and efforts to outline genetic mutations that drive the disease, lung cancer remains a leading cause of death. Even targeted treatments result in temporary remission, with patients developing drug-resistant disease later on, ...

 


Atezolizumab plus bevacizumab and chemotherapy extends PFS in non-small cell lung cancer - Healio



Reuters
 
Atezolizumab plus bevacizumab and chemotherapy extends PFS in non-small cell lung cancer 
Healio
The addition of atezolizumab to first-line treatment with bevacizumab and chemotherapy significantly prolonged PFS among individuals with advanced nonsquamous non-small cell lung cancer, according to the agent's manufacturer. Atezolizumab (Tecentriq ...
Atezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC OncLive
Roche stock up $12 billion on cancer, hemophilia trials; rivals hit Reuters
Roche reshuffles lung cancer immunotherapy market with positive clinical trial results STAT
Xconomy 
all 53 news articles » 


New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous ... - Business Wire (press release)



New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous ... 
Business Wire (press release)
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor ...

and more » 


Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval - OncLive



OncLive
 
Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval 
OncLive
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non?small-cell lung cancer. N Engl J Med. 2017;377:1919-1929. Rizvi NA, Peters S. Immunotherapy for unresectable stage III non?small-cell lung cancer. N Engl J Med.

 


Is Lung Cancer Incidence in Never-Smokers Increasing? - Medscape



Medscape
 
Is Lung Cancer Incidence in Never-Smokers Increasing? 
Medscape
Earlier this year, a group of US researchers reported that the incidence of non-small cell lung cancer (NSCLC) among never-smokers had apparently doubled over the last two decades, but a new report from Australia finds that the incidence has remained ...

 


Novel Drug Combination Hits Non-Small Cell Lung Cancer With Double Punch - Curetoday.com



Curetoday.com
 
Novel Drug Combination Hits Non-Small Cell Lung Cancer With Double Punch 
Curetoday.com
?In the initial trials, [for patients who had] larger tumors ? more than 3 centimeters ? OS and progression-free survival (PFS) was significantly improved, and significant for lung cancer means the median survival was improved by more than 2 months.

 


Phase III Trial With ZepsyreŽ in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive ... - PR Newswire (press release)



Phase III Trial With ZepsyreŽ in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive ... 
PR Newswire (press release)
PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with ZepsyreŽ (PM1183) in combination with ...

 


Changing Treatment Paradigm for BRAF-Mutant NSCLC - OncLive



OncLive
 
Changing Treatment Paradigm for BRAF-Mutant NSCLC 
OncLive
We are doing the 7-gene panel in clinical practice for nonsquamous non?small cell lung cancer. And we are moving to a 50-gene panel in a few weeks that we would like to offer systematically to all patients with non?small cell lung cancer. I agree with ...

 


'I Was Diagnosed With Lung Cancer At 19, And I'm Still Fighting It 5 Years Later' - Women's Health



Women's Health
 
'I Was Diagnosed With Lung Cancer At 19, And I'm Still Fighting It 5 Years Later' 
Women's Health
And years later, when the cancer spread to my brain and to my spine, it was still hard to fathom that a 19-year-old, healthy, active, non-smoking college student could get stage II non-small cell lung cancer in the first place. I've since learned that ...

 


Small Cell Lung Cancer Market Comprehensive Insights 2017 to 2025 - Research of Market



Small Cell Lung Cancer Market Comprehensive Insights 2017 to 2025 
Research of Market
Small Cell Lung Cancer-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Small Cell Lung Cancer. The report provides a complete understanding of the pipeline ...

and more »